AbbVie and Tentarix collaborate on oncology and immunology treatments

Betsy Goodfellow | February 23, 2024 | News story | Research and Development AbbVie, Oncology, collaboration, immunology 

AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.

The collaboration is intended to utilise AbbVie’s expertise in oncology and immunology with Tentarix’s proprietary Tentacles platform.

Under the terms of this agreement, Tentarix will receive upfront payment options with a total of $64m from AbbVie for the two programmes.

Jonathon Sedgwick PhD, senior vice president and global head of discover research at AbbVie, commented: “Oncology and immunology are two of our key strategic growth areas where we are pursuing novel technologies that aim to deliver transformative therapies, which address unmet patient needs. This strategic partnership complements our ongoing efforts in developing novel biologics, potentially to expand our oncology and immunology portfolios with conditionally-active multi-specific molecules.”

Don Santel, interim chief executive officer at Tentarix Biotherapeutics, added: “We are excited to join forces with AbbVie to help accelerate cutting-edge, conditionally-active therapeutic programmes towards clinical applications for patients in need. This collaboration adds to our portfolio of internal and external pipeline programmes and is a strong validation of our approach in understanding and targeting complex immune interactions that drive cancers and inflammatory diseases.”

Betsy Goodfellow

Related Content

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery …

Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment

Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with …

lungs

Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib

US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have …

Latest content